Monoclonal antibody therapies for cutaneous T-cell lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Pier Luigi Zinzani, MD, PhD, of University of Bologna, Bologna, Italy, discusses the clinical development of the anti-CD30 antibody-drug conjugate brentuximab vedotin and the anti-CCR4 antibody mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma.